AIRO Breast Cancer Group

#SONIA trial: CDK4/6i first-line vs second-line treatment 👇🏼 ⛔️ No statistically significant benefit for the use of CDK4/6i as a first-line 1️⃣ First line 👇🏼 💵 more cost ⚠️ more G3-4 adverse events #Breast #Cancer ⁦@OncoAlert⁩ nature.com/articles/s4158…

Role of ☢️ #radiotherapy in the multidisciplinary management of #male #breastcancer #oncoalert #radonc 👇🏼 doi.org/10.1016/j.crit…

Dose constraints in #radiotherapy #BreastCancer ⛔️ all OARs ☢️ different fractionation schedules 🩺 proposed DVCs correlated with clinical endpoints #RadOnc for a 50 days' free access 👇🏼 authors.elsevier.com/c/1j-vNcA0-Idri

💥 excellent presentations given by 🔝speakers #AIRB plenary session 👏 @PierluigiBonomo @brunomeduri @MartaScorsetti Giorgia Timon, Francesco Cellini

It has been a pleasure and an honor to report the 5-year results of #IRMA #trial at #ESTRO2024 - #APBI is not inferior to WBI in low risk #BreastCancer

It is a great pleausure to know early the results of IRMA trial which will be presented next evening by one of my best friend and colleague at ESTRO 24. Stay tuned!!!!#ESTRO24 @brunomeduri

Treatment with doxorubicin is associated with increased #Breastcancer risk in both adolescent and adult #Hodgkin #Lymphoma survivors ➡️ very long follow-up for survivors of HL needed ⁦@AiroBreast⁩ ascopubs.org/doi/10.1200/JC…

Despite 5 yr follow-up, most #cancer #drugs granted accelerated approval did not demonstrate benefit in #OS or QoL in confirmatory trials #JAMA jamanetwork.com/journals/jama/…

Primary surgery was an inferior ❌strategy vs preoperative CRT ☢️ followed by surgery, in LARC with MRI-negative MRF. It cannot be recommended in the clinical practice #rectal #cancer ⁦@OncoAlert⁩ redjournal.org/article/S0360-…

70-Gene Signature ❌NOT independently predictive of LRR. Cannot be used in clinical decision making regarding LRR #Breastcancer ⁦@OncoAlert⁩ ascopubs.org/doi/10.1200/JC…

Optimising first-line subtyping-based therapy in triple-negative #breast #cancer #TNBC (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial. Very intriguing results! ⁦@OncoAlert⁩ thelancet.com/journals/lanon…

Tumour-infiltrating lymphocyte cancer therapy nears FDA finish line #Immunotherapy nature.com/articles/d4157…

The target atlas for antibody-drug conjugates #ADC across solid #cancers | Cancer Gene Therapy nature.com/articles/s4141…

Local treatment added to systemic therapy provide a huge improvement in PFS (15·3 months vs 6·4 months) for oligometastatic #oesophageal #SCC. #radonc ⁦@OncoAlert⁩ thelancet.com/journals/langa…

Individual patient data meta-analysis of 14 324 women: Regional node RT significantly reduced breast cancer mortality and all-cause mortality #EBCTCG #radonc ⁦@OncoAlert⁩ thelancet.com/journals/lance…

#MonarchE - Adjuvant #Abemaciclib 5-years results ⬆️ IDFS benifit 7.6 % - HR 0.68 ⬆️ DRFS benifit 6.7 % - HR 0.67 ❌ no OS benefit #ESMO23 #BREASTcancer

“Old” Gem-based CRT = Folfirinox in neoadjuvant Resectable/borderline resectable #PancreaticCancer . We’re waiting for toxicity details. #radonc #PREOPANC #ESMO23

Promising novel targets for #immunotherapy in #cancer : ICOS, VISTA, TIGIT, CD112R, BTLA, TIM-3, GITR, NKG2A cancertreatmentreviews.com/article/S0305-…

9-Week Versus 1-Year Trastuzumab for Early HER2+ Breast Cancer: #ShortHER trial. 10-year DFS: 77% vs 78%. 10-year OS: 89% vs 88% ascopubs.org/doi/full/10.12…

Randomized clinical trial. In locally advanced #BreastCancer, PET-CT detected more distant metastases than conventional staging. Fewer patients received combined modality therapy of curative intent. ⁦@AiroBreast⁩ ⁦@EORTC_BCG⁩ ⁦@JCO_ASCO⁩ ascopubs.org/doi/abs/10.120…